The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
SHELTON, CT / ACCESSWIRE / August 21, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...